Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NKTR with free AI briefings, catalyst countdowns, and dilution alerts.

NKTR · NEKTAR THERAPEUTICS

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1B Cash on Hand
52.3mo Cash Runway
Follow NKTR by email Get an email when NKTR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NKTR, unsubscribe in one click. Privacy

📣 What NKTR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Etirinotecan Pegol (NKTR-102) Metastasis Phase 3 · NCT02915744 Completed
Nab-paclitaxel Metastasis Phase 3 · NCT02915744 Completed
NKTR-181 BID tablets Low Back Pain Phase 3 · NCT02367820 Completed
Bempegaldesleukin (NKTR-214) Melanoma Phase 3 · NCT03635983 Completed
Eribulin Metastasis Phase 3 · NCT02915744 Completed
Avipendekin Pegol (NKTR-255) Non-Hodgkin Lymphoma Phase 2/3 · NCT05664217 Terminated
Rezpegaldesleukin Moderate-to-Severe Atopic Dermatitis Phase 3 · NCT07711418 Recruiting
Sunitinib Renal Cell Carcinoma Phase 3 · NCT03729245 Terminated
Personalized Neoantigen Cancer Vaccine VB10.NEO Locally Advanced or Metastatic Solid Tumours Phase 1/2 · NCT03548467 Completed
NKTR-181 Osteoarthritis of the Knee Phase 2 · NCT01619839 Completed
Resiquimod Pegol (NKTR-262) Melanoma Phase 1/2 · NCT03435640 Terminated
Irinotecan Colorectal Cancer Phase 2 · NCT00856375 Completed
Dargistotug (M6223) Locally Advanced or Metastatic Urothelial Carcinoma Phase 2 · NCT05327530 Active not recruiting
JB100 Locally Advanced or Metastatic Urothelial Carcinoma Phase 2 · NCT05327530 Active not recruiting
⁸⁹Zr-Df-IAB22M2C Metastatic Melanoma Phase 1 · NCT04955262 Withdrawn
Mivavotinib Citrate (TAK-659) Lymphoma, Non-Hodgkin Phase 1 · NCT03772288 Withdrawn

Also used in these trials (approved or third-party drugs, not NKTR's own candidates): Vinorelbine, Nivolumab, Ixabepilone, Gemcitabine Hydrochloride, Paclitaxel, Docetaxel Anhydrous, Pembrolizumab, Cabozantinib, Talazoparib, Sacituzumab Govitecan, Pemetrexed Disodium, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NKTR holds $1B in cash and short-term investments (as of Jun 30, 2026) and burns about $60M/quarter from operations, an estimated runway of 52.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NKTR files for a raise →

👥 Who Owns NKTR

Insiders 0.5% Institutions (324 holders) 99.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 4,303,188 12.58% 2026-03-31
Two Seas Capital LP Institution (13G, 5%+) 3,345,978 9.78% 2026-09-25
BlackRock, Inc. Institution (13G, 5%+) 2,643,796 7.73% 2026-06-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 2,391,075 6.99% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 1,772,302 5.18% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 1,747,653 5.11% 2026-06-30
Howard W Robin
President & CEO, Director · +242,703 options
Insider 54,655 0.16% 2026-08-18
R Scott Greer
Director · +12,000 options
Insider 22,239 0.06% 2026-09-23
Mark Andrew Wilson
Chief Legal Officer · +25,066 options
Insider 21,585 0.06% 2025-11-21
Roy A Whitfield
Director · +12,000 options
Insider 21,185 0.06% 2026-09-23
Robert Chess
Director · +12,000 options
Insider 19,299 0.06% 2026-09-23
Jonathan Zalevsky
Chief R&D Officer · +62,932 options
Insider 9,570 0.03% 2026-08-18

Share count 34,214,683 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NKTR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NKTR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.